AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer

NCT00089661 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

252

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
Low Bone Mineral Density
Osteopenia

Interventions

DRUG: Placebo
DRUG: AMG 162 / Denosumab

Sponsor

Amgen